ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract manufacturing for other pharmaceutical companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was founded in 2001 and is headquartered in Baudette, Minnesota.
IPO Year:
Exchange: NASDAQ
Website: anipharmaceuticals.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
3/15/2024 | $80.00 | Overweight | CapitalOne |
8/22/2023 | $60.00 → $73.00 | Buy | H.C. Wainwright |
3/1/2023 | $55.00 | Buy | Guggenheim |
9/7/2022 | $50.00 | Buy | H.C. Wainwright |
11/2/2021 | $60.00 → $65.00 | Outperform | Raymond James |
11/2/2021 | $70.00 | Buy | Truist |
PRINCETON, N.J., Sept. 13, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced the launch of Promethazine Hydrochloride and Dextromethorphan Hydrobromide Oral Solution, 6.25 mg/15 mg per 5 mL. "The launch of Promethazine Hydrochloride and Dextromethorphan Hydrobromide Oral Solution just prior to the onset of cough and cold season is especially timely. With our 14th new product launch this year, we continue to drive strong growth in our Generics business," stated Nikhil Lalwani, President and Chief Executive Officer of ANI. U.S. annual sales for Promethazine Hydrochloride and Dextromethorphan Hydrobromide Oral Solution total approximately
PRINCETON, N.J. and ATLANTA, Sept. 11, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) ("ANI") and Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera" or the "Company") today jointly announced that they have scheduled the closing of their transaction pursuant to the companies' previously announced Merger Agreement for before the market opens on Monday, September 16, 2024. About ANI Pharmaceuticals, Inc.ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) is a diversified biopharmaceutical company serving patients in need by developing, manufacturing, and marketing high-quality branded and generic prescription pharmaceutical products, including for diseases with high unmet medic
PRINCETON, N.J., Sept. 10, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. ("ANI" or "the Company") (NASDAQ:ANIP) today provided an update on the status of the completion of its previously announced acquisition of Alimera Sciences, Inc. ("Alimera") (NASDAQ:ALIM). We note the Alimera press release issued today. The Company continues to work in good faith toward closing of the acquisition. Any delay is a result of discussions regarding closing conditions, which the Company expects to resolve promptly. About ANI Pharmaceuticals, Inc. ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) is a diversified biopharmaceutical company serving patients in need by developing, manufacturing, and marketing hig
Alimera Has Filed Lawsuit in the Delaware Court of Chancery to Compel ANI to Close Merger Transaction and Honor its Contractual Obligations Alimera Shareholders Approved Merger Agreement on September 4, Clearing Last Requirement for Closing Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announced that it has filed a lawsuit in the Delaware Court of Chancery (the "Court") to compel ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) ("ANI") to fulfill its contractual obligation to close the transaction contemplated by the co
PRINCETON, N.J., Aug. 13, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced the closing of its offering of $316,250,000 aggregate principal amount of 2.25% convertible senior notes due 2029 (the "notes") in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). In response to investor demand, ANI upsized the initial offering of $250,000,000 aggregate principal amount of notes to $275,000,000 and the initial purchasers fully exercised their option to purchase an additional $41,250,000 aggregate principal amount of the notes. The notes were issued pursu
PRINCETON, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced the pricing of its offering of $275,000,000 aggregate principal amount of 2.25% convertible senior notes due 2029 (the "notes") in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The offering size was increased from the previously announced offering size of $250,000,000 aggregate principal amount of notes. The issuance and sale of the notes are scheduled to settle on August 13, 2024, subject to customary closing conditions. ANI also granted the initial purchasers of the
PRINCETON, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced its intention to offer, subject to market and other conditions, $250,000,000 aggregate principal amount of convertible senior notes due 2029 (the "notes") in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). ANI also expects to grant the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $37,500,000 principal amount
Generated record quarterly net revenues of $138.0 million, representing year-over-year growth of 18.4%, and record Rare Disease net revenues of $49.2 million, an increase of 102.4% year-over-yearDelivered adjusted non-GAAP EBITDA of $33.2 million, and adjusted non-GAAP diluted earnings per share of $1.02Net loss available to common shareholders of $(2.7) million and diluted GAAP loss per share of $(0.14)On track to close acquisition of Alimera Sciences, Inc. in the third quarter of 2024, adding two durable commercial assets ILUVIEN® and YUTIQ® with significant growth potential to its Rare Disease portfolioIncreased 2024 guidance with expected net revenues of $540 million to $560 million, adj
PRINCETON, N.J., July 31, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (NASDAQ:ANIP) today announced that the Company will release its second quarter 2024 financial results on Tuesday, August 6, 2024, prior to the market open. Nikhil Lalwani, President and Chief Executive Officer, and Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, will host a conference call to discuss the results as follows: DateTuesday, August 6, 2024 Time8:30 a.m. ET Toll free (U.S.)800-245-3047 Conference ID4619279 Webcast (live and replay)www.anipharmaceuticals.com, under the "Investors" section A replay of the conference call will be available with
PRINCETON, N.J., July 15, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced that following final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), the Company launched L-Glutamine Oral Powder. ANI's L-Glutamine Oral Powder is the generic version of the reference listed drug (RLD) Endari®. "The approval and launch of L-Glutamine Oral Powder, the first AA-rated approved generic to Endari®, continues to demonstrate the strong capabilities and execution of our R&D team. We remain focused on ensuring that patients in need, and the providers who care for them, have access to our high-qua
4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)
4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)
4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)
4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)
4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)
4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)
4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)
4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)
4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)
4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)
CapitalOne initiated coverage of ANI Pharma with a rating of Overweight and set a new price target of $80.00
H.C. Wainwright reiterated coverage of ANI Pharma with a rating of Buy and set a new price target of $73.00 from $60.00 previously
Guggenheim initiated coverage of ANI Pharma with a rating of Buy and set a new price target of $55.00
H.C. Wainwright initiated coverage of ANI Pharma with a rating of Buy and set a new price target of $50.00
Raymond James reiterated coverage of ANI Pharmaceuticals with a rating of Outperform and set a new price target of $65.00 from $60.00 previously
Truist initiated coverage of ANI Pharma with a rating of Buy and set a new price target of $70.00
Raymond James reiterated coverage of ANI Pharmaceuticals with a rating of Outperform and set a new price target of $60.00 from $40.00 previously
Generated record quarterly net revenues of $138.0 million, representing year-over-year growth of 18.4%, and record Rare Disease net revenues of $49.2 million, an increase of 102.4% year-over-yearDelivered adjusted non-GAAP EBITDA of $33.2 million, and adjusted non-GAAP diluted earnings per share of $1.02Net loss available to common shareholders of $(2.7) million and diluted GAAP loss per share of $(0.14)On track to close acquisition of Alimera Sciences, Inc. in the third quarter of 2024, adding two durable commercial assets ILUVIEN® and YUTIQ® with significant growth potential to its Rare Disease portfolioIncreased 2024 guidance with expected net revenues of $540 million to $560 million, adj
PRINCETON, N.J., July 31, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (NASDAQ:ANIP) today announced that the Company will release its second quarter 2024 financial results on Tuesday, August 6, 2024, prior to the market open. Nikhil Lalwani, President and Chief Executive Officer, and Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, will host a conference call to discuss the results as follows: DateTuesday, August 6, 2024 Time8:30 a.m. ET Toll free (U.S.)800-245-3047 Conference ID4619279 Webcast (live and replay)www.anipharmaceuticals.com, under the "Investors" section A replay of the conference call will be available with
Conference call scheduled for today at 8:30 a.m. ET Strengthens Rare Disease segment as largest driver of future growth, expected to add approximately $105 million in highly durable branded revenueAdds two commercial assets ILUVIEN® and YUTIQ® with significant growth potential, expanding ANI's foothold in key strategic therapeutic area of ophthalmology Anticipated to drive high single digit to low double digit accretion in adjusted non-GAAP EPS in 2025 and to be substantially accretive thereafterExpected to generate additional $35 - $38 million in 2025 adjusted non-GAAP EBITDA inclusive of approximately $10 million in identified cost synergies; additional EBITDA contribution expected from a
BAUDETTE, Minn., April 18, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (NASDAQ:ANIP) today announced that the Company will release its first quarter 2024 financial results on Friday, May 10, 2024, prior to the market open. Nikhil Lalwani, President and Chief Executive Officer, and Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, will host a conference call to discuss the results as follows: DateFriday, May 10, 2024 Time8:30 a.m. ET Toll free (U.S.)800-274-8461 Conference ID4555224 Webcast (live and replay)www.anipharmaceuticals.com, under the "Investors" section A replay of the conference call will be available within two
Generated quarterly net revenues of $131.7 million, representing year-over-year growth of 39.7%, net income to common shareholders of $0.7 million, GAAP diluted earnings per share of $0.04Delivered adjusted non-GAAP EBITDA of $30.2 million, and adjusted non-GAAP diluted earnings per share of $1.00Rare Disease business delivered Q4 net revenues of $41.7 million, representing quarter-over-quarter growth of 40.4% and year-over-year growth of 137.3%Generated $119.0 million in cash from operating activities during the year, ending Q4 with $221.1 million in cash2024 guidance issued with net revenues of $520 million to $542 million, adjusted non-GAAP EBITDA of $135 million to $145 million and adjus
BAUDETTE, Minn., Feb. 07, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (NASDAQ:ANIP) today announced that the Company will release its fourth quarter and full year 2023 financial results on Thursday, February 29, 2024, prior to the market open. Nikhil Lalwani, President and Chief Executive Officer, and Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, will host a conference call to discuss the results as follows: Date Thursday, February 29, 2024 Time 8:30 a.m. ET Toll free (U.S.) 800-274-8461 Webcast (live and replay) www.anipharmaceuticals.com, under the "Investors" section A replay of the conference call will be availa
Third Quarter 2023 Financial Results -- Record quarterly net revenues of $131.8 million, representing year-over-year growth of 57.3%; net income available to common shareholders of $9.5 million and diluted GAAP income per share of $0.45 -- -- Record quarterly adjusted non-GAAP EBITDA of $36.5 million representing year-over-year growth of 98.3%; adjusted non-GAAP diluted earnings per share of $1.27 -- -- Lead Rare Disease asset, Purified Cortrophin® Gel (Repository Corticotrophin Injection USP) 80 U/ml (Cortrophin Gel) reported net sales of $29.7 million, a year-over-year increase of 135.9% -- -- Generics, Established Brands and Other reported net sales of $102.1 million, representing yea
BAUDETTE, Minn., Oct. 25, 2023 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (NASDAQ:ANIP) today announced that the Company will release its third quarter 2023 financial results on Wednesday, November 8, 2023, prior to the market open. Nikhil Lalwani, President and Chief Executive Officer, and Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, will host a conference call to discuss the results as follows: Date Wednesday, November 8, 2023 Time 8:30 a.m. ET Toll free (U.S.) 800-445-7795 Webcast (live and replay) www.anipharmaceuticals.com, under the "Investors" section A replay of the conference call will be available wit
Second Quarter 2023 Financial Results -- Record quarterly net revenues of $116.5 million, representing year-over-year growth of 57.8%; net income available to common shareholders of $5.8 million and diluted GAAP income per share of $0.29 -- -- Record quarterly adjusted non-GAAP EBITDA of $34.1 million representing year-over-year growth of 246.0%; adjusted non-GAAP diluted earnings per share of $1.28 -- -- Lead Rare Disease asset, Purified Cortrophin® Gel (Repository Corticotrophin Injection USP) 80 U/ml (Cortrophin Gel) reported net sales of $24.3 million, a year-over-year increase of 138.2% -- -- Generics, Established Brands and Others reported net sales of $92.2 million, representing y
BAUDETTE, Minn., July 31, 2023 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (NASDAQ:ANIP) today announced that the Company will release its second quarter 2023 financial results on Wednesday, August 9, 2023, prior to the market open. Nikhil Lalwani, President and Chief Executive Officer, and Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, will host a conference call to discuss the results as follows: DateWednesday, August 9, 2023Time8:30 a.m. ETToll free (U.S.)800-267-6316Webcast (live and replay)www.anipharmaceuticals.com, under the "Investors" section A replay of the conference call will be available within two hours of the call's
8-K - ANI PHARMACEUTICALS INC (0001023024) (Filer)
8-K - ANI PHARMACEUTICALS INC (0001023024) (Filer)
8-K - ANI PHARMACEUTICALS INC (0001023024) (Filer)
10-Q - ANI PHARMACEUTICALS INC (0001023024) (Filer)
8-K - ANI PHARMACEUTICALS INC (0001023024) (Filer)
S-8 - ANI PHARMACEUTICALS INC (0001023024) (Filer)
8-K - ANI PHARMACEUTICALS INC (0001023024) (Filer)
144 - ANI PHARMACEUTICALS INC (0001023024) (Subject)
8-K - ANI PHARMACEUTICALS INC (0001023024) (Filer)
8-K - ANI PHARMACEUTICALS INC (0001023024) (Filer)
ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced that following final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), the Company launched L-Glutamine Oral Powder. ANI's L-Glutamine Oral Powder is the generic version of the reference listed drug (RLD) Endari®. "The approval and launch of L-Glutamine Oral Powder, the first AA-rated approved generic to Endari®, continues to demonstrate the strong capabilities and execution of our R&D team. We remain focused on ensuring that patients in need, and the providers who care for them, have access to our high-quality therapeutics," stated Nikhil Lalwani, Presiden
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Citigroup raised the price target for NVIDIA Corporation (NASDAQ:NVDA) from $126 to $150. Citigroup analyst Atif Malik maintained a Buy rating. NVIDIA shares gained 6.8% to close at $126.09 on Tuesday. See how other analysts view this stock. Truist Securities raised the price target for Rivian Automotive, Inc. (NASDAQ:RIVN) from $10 to $13. Truist Securities analyst Jordan Levy maintained a Hold rating. Rivian Automotive shares gained 8.6% to close at $11.96 on Tuesday. See how other analysts view
HC Wainwright & Co. analyst Oren Livnat maintains ANI Pharmaceuticals (NASDAQ:ANIP) with a Buy and raises the price target from $87 to $94.
The CNN Money Fear and Greed index showed some improvement in the overall market sentiment, while the index remained in the “Fear” zone on Monday. U.S. stocks closed mixed on Monday, with the Dow Jones index surging more than 250 points during the session. However, the Nasdaq Composite recorded its worst session since April. Last week, the S&P 500 recorded a gain of 0.6%, while the Dow Jones index gained 1.45% to record its strongest weekly performance since May. On the economic data front, the Federal Reserve Bank of Dallas' general business activity index for manufacturing in Texas improved to -15.1 in June compared to -19.4 in May. Shares of NVIDIA Corporation (NASDAQ:NVDA) fe
On Monday, ANI Pharmaceuticals Inc (NASDAQ:ANIP) agreed to acquire Alimera Sciences Inc (NASDAQ:ALIM) for $5.50 per share in cash and one non-tradable contingent value right (CVR) of up to $0.50 per share upon the achievement of certain net revenue targets in 2026 and 2027. ANI will also repay $72.5 million of Alimera debt. The transaction, which values Alimera at approximately $381 million in upfront consideration, has been approved by both the ANI and Alimera Boards of Directors and is expected to close late in the third quarter of 2024. Alimera’s two commercial products include Iluvien (fluocinolone acetonide intravitreal implant 0.19mg) is indicated for diabetic macular edem
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) ("ANI" or the "Company") and Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera") today announced they have signed a definitive agreement pursuant to which ANI will acquire Alimera for $5.50 per share in cash at closing and one non-tradable contingent value right (CVR) representing the right to receive up to $0.50 per share upon the achievement of certain net revenue targets in 2026 and 2027. The transaction, which values Alimera at approximately $381 million in up front consideration, has been approved by both the ANI and Alimera Boards of Directors and is expected to close late in the third quarter of 2024, as further described below. Alimera is a globa
U.S. annual sales for Sodium Polystyrene Sulfonate Oral / Rectal Suspension total approximately $30.3 million, based on March 2024 moving annual total (MAT) IQVIA data.
HC Wainwright & Co. analyst Oren Livnat maintains ANI Pharmaceuticals (NASDAQ:ANIP) with a Buy and raises the price target from $83 to $87.
ANI continues to expect total company adjusted non-GAAP gross margin between 62% and 63% and the Company will continue to tax effect non-GAAP adjustments for computation of adjusted non-GAAP diluted earnings per share at a tax rate of 26.0%. The Company now anticipates between 19.4 million and 19.7 million shares outstanding (reflective of a full year of shares outstanding resulting from the May 2023 equity raise) for the purpose of calculating diluted EPS and now expects its U.S. GAAP effective tax rate to be between 22.0% to 25.0% as compared to 20.0% to 22.0%.
Submission status for ANI PHARMS INC's drug HYDROCODONE BITARTRATE AND IBUPROFEN (SUPPL-6) with active ingredient HYDROCODONE BITARTRATE; IBUPROFEN has changed to 'Approval' on 03/04/2021. Application Category: ANDA, Application Number: 077454, Application Classification: Labeling
Submission status for ANI PHARMS INC's drug OXYCODONE AND ASPIRIN (SUPPL-30) with active ingredient ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE has changed to 'Approval' on 03/04/2021. Application Category: ANDA, Application Number: 040255, Application Classification: Labeling
Submission status for ANI PHARMS INC's drug EZETIMIBE AND SIMVASTATIN (SUPPL-10) with active ingredient EZETIMIBE; SIMVASTATIN has changed to 'Approval' on 02/23/2021. Application Category: ANDA, Application Number: 201890, Application Classification: Labeling
Submission status for ANI PHARMS INC's drug TEMOZOLOMIDE (SUPPL-9) with active ingredient TEMOZOLOMIDE has changed to 'Approval' on 01/04/2021. Application Category: ANDA, Application Number: 203490, Application Classification: Labeling
SC 13D/A - ANI PHARMACEUTICALS INC (0001023024) (Subject)
SC 13G - ANI PHARMACEUTICALS INC (0001023024) (Subject)
SC 13G - ANI PHARMACEUTICALS INC (0001023024) (Subject)
SC 13D/A - ANI PHARMACEUTICALS INC (0001023024) (Subject)
SC 13D/A - ANI PHARMACEUTICALS INC (0001023024) (Subject)
SC 13D/A - ANI PHARMACEUTICALS INC (0001023024) (Subject)
SC 13G/A - ANI PHARMACEUTICALS INC (0001023024) (Subject)
SC 13D/A - ANI PHARMACEUTICALS INC (0001023024) (Subject)
SC 13D - ANI PHARMACEUTICALS INC (0001023024) (Subject)
-- Mr. Leonard is an accomplished leader with 35 years of pharmaceuticals and healthcare experience -- Mr. Leonard has significant expertise in pharmacy benefits management, health insurance, and specialty and retail pharmacy -- BAUDETTE, Minn., Aug. 23, 2023 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced the addition of Matthew J. Leonard, R.Ph. to its Board of Directors. Mr. Leonard brings more than 35 years of experience as an accomplished leader and innovator within the pharmaceutical industry. This appointment is effective immediately. "We are delighted to add Matthew (Matt) Leonard to our Board of Directors. With his deep leadershi
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) ("ANI" or the "Company") today announced that Krista L. Davis will join the Company as Chief Human Resources Officer, effective September 12. Ms. Davis brings to the Company over 20 years of executive leadership experience in human resources, talent management, and organizational development. "Ms. Davis is an important addition to our leadership team and will bring strategic and innovative thought leadership to our priority people and organizational issues. Krista has a long track record of driving organizational effectiveness and delivering results across industries and cultures, most recently with Novartis, where she led global human resources for
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) (ANI or the Company) today announced that Meredith W. Cook will join the Company as SVP, General Counsel and Corporate Secretary, effective July 18. Ms. Cook brings over 20 years of legal and leadership experience in specialty and generics pharmaceuticals, including in corporate governance, mergers and acquisitions (M&A), strategic transactions, and intellectual property (IP). "We are delighted to welcome Ms. Cook to our leadership team. Meredith is an accomplished attorney with demonstrated leadership and expertise in the pharmaceutical industry and will no doubt play an important role in the Company's continued growth. Her guidance and perspectives
-- Dr. Tannenbaum's successful track record in driving commercial excellence to contribute as Company executes Purified Cortrophin GelTM launch -- ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) (ANI or the Company) today announced the addition of Renee P. Tannenbaum, Pharm.D., MBA, to its Board of Directors. Dr. Tannenbaum has over 35 years of management experience in the pharmaceutical industry. This appointment is effective immediately and increases ANI's Board of Directors to nine members. "We are honored to bring Dr. Tannenbaum's vast biopharmaceutical commercial experience and expertise to our Board of Directors. With her many accomplishments and proven track record of developing and implem
-- ANI Pharmaceuticals appoints Mary Pao, M.D., Ph.D., as Chief Medical Officer, Rare Disease, and Elizabeth Powell, J.D., as Chief Compliance Officer and Head of Legal, Rare Disease -- -- Dr. Pao and Ms. Powell, collectively, bring four decades of pharmaceutical industry experience to their roles in support of the commercialization of Purified Cortrophin™ Gel (repository corticotropin injection USP) -- -- Rare Disease Business Unit leadership hires build on recent Cortrophin Gel milestones -- ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) (ANI or the Company) today announced two additions to its Rare Disease Business Unit leadership team. Mary Pao, M.D., Ph.D., has been appointed Chief Medical